Single‑Inhaler Triple Therapy for High‑Risk COPD Patients

Guideline Recommendations

• The Canadian Thoracic Society (2023) recommends single‑inhaler triple therapy for patients at high risk of COPD exacerbations and states that this approach may reduce mortality in individuals with moderate‑to‑severe disease. Strong recommendation. 1

Evidence of Mortality Benefit

• In the IMPACT randomized trial, fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) reduced all‑cause mortality compared with LAMA/LABA dual therapy (risk ratio 0.64; 95 % CI 0.42–0.97), providing trial‑level support for preferring this regimen in high‑risk patients. Level A evidence. 4

Safety Considerations – Pneumonia

• Both inhaled‑corticosteroid‑containing triple therapies increase the incidence of pneumonia, with an estimated number needed to harm of approximately 33 patients per year. Moderate certainty. 4

• The increased pneumonia risk must be balanced against the exacerbation‑reduction benefit, particularly in older adults and in patients with a prior history of pneumonia. Clinical judgment advised. 5